OLMA

SEC source: 0001871145-26-000006 · form4-09022026_040901.xml · derivative · entry 1

O'Byrne Jason · CIK 0001871145 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 650,000

Underlying: Common Stock · 650,000 shares

Expires 2036-08-31

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on August 11, 2027 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001831410-26-000008 · form4-07272026_070701.xml · nonDerivative · entry 2

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 702,770

F2 · price: The weighted average sale price for the transaction reported was $11.714, and the range of prices were between $11.70 and $11.775. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001831410-26-000008 · form4-07272026_070701.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 715,270

F1 · price: The weighted average sale price for the transaction reported was $11.579, and the range of prices were between $11.52 and $11.675. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0000921895-26-001653 · form407422010_06232026.xml · derivative · entry 5

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · Director · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · Director · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · Director · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · Director · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 29,500

Underlying: Common stock, $0.0001 par value · 29,500 shares

Expires 2036-06-18

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F7 · security: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

F9 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to Dr. Hrustanovic's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to Dr. Hrustanovic's continuous service through such vesting date.

F1 · derivative.underlying: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F7 · ownership.direct: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

F7 · ownership.nature: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

SEC source: 0001162157-26-000002 · form4-06232026_090631.xml · derivative · entry 1

RAPPAPORT ANDREW · CIK 0001162157 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,500

Underlying: Common Stock · 29,500 shares

Expires 2036-06-18

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001638709-26-000004 · form4-06232026_090644.xml · derivative · entry 1

Horning Sandra · CIK 0001638709 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,500

Underlying: Common Stock · 29,500 shares

Expires 2036-06-18

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001222082-26-000004 · form4-06232026_090608.xml · derivative · entry 1

BUTITTA CYNTHIA M · CIK 0001222082 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,500

Underlying: Common Stock · 29,500 shares

Expires 2036-06-18

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001336504-26-000006 · form4-06232026_090631.xml · derivative · entry 1

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,500

Underlying: Common Stock · 29,500 shares

Expires 2036-06-18

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001533228-26-000008 · form4-06232026_090620.xml · derivative · entry 1

Garland J. Scott · CIK 0001533228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,500

Underlying: Common Stock · 29,500 shares

Expires 2036-06-18

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001831410-26-000006 · form4-06232026_090619.xml · derivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,500

Underlying: Common Stock · 29,500 shares

Expires 2036-06-18

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001821194-26-000002 · form4-06232026_090627.xml · derivative · entry 1

Hrustanovic Gorjan · CIK 0001821194 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,500

Underlying: Common Stock · 29,500 shares

Expires 2036-06-18

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

F2 · ownership.direct: The Reporting Person is a member of BVF Partners L.P. ("BVF") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001785987-26-000002 · form4-06232026_090642.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,500

Underlying: Common Stock · 29,500 shares

Expires 2036-06-18

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0002018686-26-000010 · form4-06232026_090648.xml · derivative · entry 1

Raman Prakash · CIK 0002018686 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,500

Underlying: Common Stock · 29,500 shares

Expires 2036-06-18

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001777517-26-000002 · form4-06232026_090610.xml · derivative · entry 1

Graham G. Walmsley · CIK 0001777517 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,500

Underlying: Common Stock · 29,500 shares

Expires 2036-06-18

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0002018686-26-000006 · form4-04292026_110437.xml · derivative · entry 2

Raman Prakash · CIK 0002018686 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,150

Underlying: Common Stock · 24,150 shares

Expires 2036-04-27

F2 · derivative.exercise_date: The shares subject to the option vest in a series of 36 successive equal monthly installments measured from April 28, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0002018686-26-000006 · form4-04292026_110437.xml · derivative · entry 1

Raman Prakash · CIK 0002018686 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,911

Underlying: Common Stock · 2,911 shares

Expires 2036-04-27

F1 · derivative.exercise_date: The shares subject to the option vest in full on June 11, 2026, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001749432-26-000004 · form4-03052026_080301.xml · derivative · entry 7

Mitchell Shawnte · CIK 0001749432 · CHIEF LEGAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 410,000

Underlying: Common Stock · 25,000 shares

Expires 2035-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001749432-26-000004 · form4-03052026_080301.xml · nonDerivative · entry 5

Mitchell Shawnte · CIK 0001749432 · CHIEF LEGAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F3 · price: The weighted average sale price for the transaction reported was $24.69, and the range of prices were between $24.68 and $24.70. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001749432-26-000004 · form4-03052026_080301.xml · nonDerivative · entry 4

Mitchell Shawnte · CIK 0001749432 · CHIEF LEGAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 233

F2 · price: The weighted average sale price for the transaction reported was $24.25, and the range of prices were between $23.68 and $24.64. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001749432-26-000004 · form4-03052026_080301.xml · nonDerivative · entry 3

Mitchell Shawnte · CIK 0001749432 · CHIEF LEGAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001749432-26-000004 · form4-03052026_080301.xml · derivative · entry 6

Mitchell Shawnte · CIK 0001749432 · CHIEF LEGAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 435,000

Underlying: Common Stock · 15,000 shares

Expires 2035-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001749432-26-000004 · form4-03052026_080301.xml · nonDerivative · entry 2

Mitchell Shawnte · CIK 0001749432 · CHIEF LEGAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: The weighted average sale price for the transaction reported was $23.01, and the range of prices were between $22.89 and $23.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001749432-26-000004 · form4-03052026_080301.xml · nonDerivative · entry 1

Mitchell Shawnte · CIK 0001749432 · CHIEF LEGAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001749432-26-000002 · form4-02042026_090203.xml · derivative · entry 2

Mitchell Shawnte · CIK 0001749432 · CHIEF LEGAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,250

Underlying: Common Stock · 56,250 shares

Expires 2036-02-01

F2 · derivative.exercise_date: The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date.

SEC source: 0001749432-26-000002 · form4-02042026_090203.xml · derivative · entry 1

Mitchell Shawnte · CIK 0001749432 · CHIEF LEGAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,000

Underlying: Common Stock · 220,000 shares

Expires 2036-02-01

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001905871-26-000002 · form4-02042026_090207.xml · derivative · entry 2

Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,250

Underlying: Common Stock · 106,250 shares

Expires 2036-02-01

F2 · derivative.exercise_date: The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date.

SEC source: 0001905871-26-000002 · form4-02042026_090207.xml · derivative · entry 1

Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2036-02-01

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001831216-26-000005 · form4-02042026_090205.xml · derivative · entry 2

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,250

Underlying: Common Stock · 106,250 shares

Expires 2036-02-01

F2 · derivative.exercise_date: The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date.

SEC source: 0001831216-26-000005 · form4-02042026_090205.xml · derivative · entry 1

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2036-02-01

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001831218-26-000002 · form4-02042026_090201.xml · derivative · entry 2

Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 275,000 shares

Expires 2036-02-01

F2 · derivative.exercise_date: The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date.

F3 · derivative.exercise_date: Notwithstanding the foregoing, if the Reporting Person's continuous service is terminated without Cause (as defined in the Reporting Person's offer letter), the performance-based stock options shall remain outstanding and eligible to vest for twelve (12) months following such termination.

SEC source: 0001831218-26-000002 · form4-02042026_090201.xml · derivative · entry 1

Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 850,000

Underlying: Common Stock · 850,000 shares

Expires 2036-02-01

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0002110895-26-000005 · form4-02182026_020201.xml · derivative · entry 2

Austin Sasha Lu · CIK 0002110895 · VP of Finance and Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,250

Underlying: Common Stock · 29,250 shares

Expires 2036-02-01

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0002110895-26-000005 · form4-02182026_020201.xml · nonDerivative · entry 1

Austin Sasha Lu · CIK 0002110895 · VP of Finance and Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,188

SEC source: 0001831410-26-000004 · form4-01212026_090101.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 727,770

F1 · price: 2. The weighted average sale price for the transaction reported was $26.88, and the range of prices were between $26.85 and $26.96. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001579397-26-000002 · form4-01152026_090101.xml · nonDerivative · entry 2

Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,727

F2 · price: The weighted average purchase price for the transaction reported was $28.73, and the range of prices were between $28.50 and $29.18. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001831216-26-000003 · form4-01142026_090101.xml · derivative · entry 10

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2033-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001831216-26-000003 · form4-01142026_090101.xml · nonDerivative · entry 7

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 542,761

F6 · price: The weighted average sale price for the transaction reported was $28.99, and the range of prices was between $28.80 and $29.39. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001831216-26-000003 · form4-01142026_090101.xml · nonDerivative · entry 6

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 577,764

F5 · price: The weighted average sale price for the transaction reported was $28.60, and the range of prices was between $27.80 and $28.79. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001831216-26-000003 · form4-01142026_090101.xml · nonDerivative · entry 5

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 592,761

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001831410-26-000002 · form4-01162026_090101.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 737,770

F1 · price: The weighted average sale price for the transaction reported was $29.12, and the range of prices were between $29.00 and $29.23. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001831216-26-000003 · form4-01142026_090101.xml · derivative · entry 9

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 50,000 shares

Expires 2033-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001831216-26-000003 · form4-01142026_090101.xml · nonDerivative · entry 4

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 542,761

SEC source: 0001831216-26-000003 · form4-01142026_090101.xml · nonDerivative · entry 3

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 542,961

F4 · price: The weighted average purchase price for the transaction reported was $27.60, and the range of prices were between $27.35 and $28.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001831216-26-000003 · form4-01142026_090101.xml · nonDerivative · entry 2

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 592,761

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · balance_after: On December 23, 2025, the Reporting Person filed a Form 4 that contained a scrivener's error that resulted in the number of shares beneficially owned directly by the Reporting Person to be overstated by 120 shares. That error has been corrected in this Form 4.

SEC source: 0001579397-26-000002 · form4-01152026_090101.xml · nonDerivative · entry 1

Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 239,727

F1 · price: The weighted average sale price for the transaction reported was $28.01, and the range of prices were between $28.00 and $28.03. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001831216-26-000003 · form4-01142026_090101.xml · nonDerivative · entry 1

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 144,846

F1 · price: The weighted average sale price for the transaction reported was $28.34, and the range of prices were between $28.07 and $28.66. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

F2 · ownership.nature: The shares are held by Myles Properties Inc., of which the Reporting Person is President.

SEC source: 0001831218-25-000004 · form4-12302025_091209.xml · nonDerivative · entry 1

Bohen Sean · CIK 0001831218 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 237,650

F1 · kind: Reflects the gift of common stock to a charitable donor advised fund.

F2 · balance_after: Includes 4,488 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025.

SEC source: 0001905871-25-000004 · form4-12242025_021251.xml · derivative · entry 12

Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,818

Underlying: Common Stock · 50,000 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: 25% of the shares subject to the option vested on January 31, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001905871-25-000004 · form4-12242025_021251.xml · nonDerivative · entry 8

Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,488

F5 · price: The weighted average sale price for the transaction reported was $27.66, and the range of prices was between $27.50 and $27.83. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001905871-25-000004 · form4-12242025_021251.xml · nonDerivative · entry 7

Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,997

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.